Resveratrol Alleviates Arsenic Exposure-Induced Liver Fibrosis in Rats by Inhibiting Hepatocyte Senescence
- PMID: 38831176
- DOI: 10.1007/s12011-024-04255-9
Resveratrol Alleviates Arsenic Exposure-Induced Liver Fibrosis in Rats by Inhibiting Hepatocyte Senescence
Abstract
Arsenic is an environmental pollutant that has garnered considerable attention from the World Health Organization. Liver fibrosis is an advanced pathological stage of liver injury that can be caused by chronic arsenic exposure and has the potential to be reversed to prevent cirrhosis and hepatic malignancies. However, effective treatment options are currently limited. Given the profibrogenic effect of hepatocyte senescence, we established a rat model of sub-chronic sodium arsenite exposure and investigated the ability of resveratrol (RSV), a potential anti-senescence agent, to ameliorate arsenic-induced liver fibrosis and elucidate the underlying mechanism from the perspective of hepatocyte senescence. The results demonstrated that RSV was capable of mitigating fibrosis phenotypes in rat livers, including the activation of hepatic stellate cell (HSC), the generation of extracellular matrix, and the deposition of collagen fibers in the liver vascular zone, which are all induced by arsenic exposure. Furthermore, as an activator of the longevity factor SIRT1, RSV antagonized the arsenic-induced inhibition of SIRT1 expression, thereby restoring the suppression of the senescence protein p16 by SIRT1. This prevented arsenic-induced hepatocyte senescence, manifesting as a decrease in telomere shortening and a reduction in the release of senescence-associated secretory phenotype (SASP)-related proteins. In conclusion, this study demonstrated that RSV counteracts arsenic-induced hepatocyte senescence and the release of SASP-related proteins by restoring the inhibitory effect of SIRT1 on p16, thereby suppressing the activation of fibrotic phenotypes and mitigating liver fibrosis. These findings provide new insights for understanding the mechanism of arsenic-induced liver fibrosis, and more importantly, they reveal novel potential interventional approaches.
Keywords: Arsenic; Cellular senescence; Liver fibrosis; Resveratrol; SIRT1.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical Approval and Consent to Participate: All procedures involving animal experiments were performed in accordance with ethical standards and were approved by the Research Ethics Committee of Guizhou Medical University (Approval No. 1702146). Competing interests: The authors declare no competing interests.
References
-
- Carlin DJ, Naujokas MF, Bradham KD, Cowden J, Heacock M, Henry HF et al (2016) Arsenic and environmental health: state of the science and future research opportunities. Environ Health Perspect 124:890–899. https://doi.org/10.1289/ehp.1510209 - DOI - PubMed
-
- Chen QY, Costa M (2021) Arsenic: a global environmental challenge. Annu Rev Pharmacol Toxicol 61:47–63. https://doi.org/10.1146/annurev-pharmtox-030220-013418 - DOI - PubMed
-
- Yao M, Zeng Q, Luo P, Sun B, Liang B, Wei S et al (2021) Assessing the risk of coal-burning arsenic-induced liver damage: a population-based study on hair arsenic and cumulative arsenic. Environ Sci Pollut Res Int 28:50489–50499. https://doi.org/10.1007/s11356-021-14273-y - DOI - PubMed
-
- Mazumder DN (2005) Effect of chronic intake of arsenic-contaminated water on liver. Toxicol Appl Pharmacol 206:169–175. https://doi.org/10.1016/j.taap.2004.08.025 - DOI - PubMed
-
- Hsu LI, Wang YH, Hsieh FI, Yang TY, Wen-Juei Jeng R, Liu CT et al (2016) Effects of arsenic in drinking water on risk of hepatitis or cirrhosis in persons with and without chronic viral hepatitis. Clin Gastroenterol Hepatol 14:1347-1355.e1344. https://doi.org/10.1016/j.cgh.2016.03.043 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
